Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas

NCT04248231 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT04248231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04248231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas
Lead sponsor
Institut Claudius Regaud
Phase
Observational
Overall status
Completed
Start date
September 15, 2019
Completion date
December 23, 2021
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian adenocarcinoma